Although a significant enrichment of p53 was observed in both ARP-sEVs and CDP-sEVs, their anti-tumor activities varied (Figure 4E–G); the variation in their anti-tumor effects likely stems from differences in the recipient cells’ p53 uptake and processing post-sEV delivery. The gene discussed is TP53; the disease is neoplasm.